Skip to main content

Advertisement

Table 5 Clinical findings in dogs of treated and control groups following the first treatment

From: Safety of fluralaner chewable tablets (BravectoTM), a novel systemic antiparasitic drug, in dogs after oral administration

Observation Number of dogs affected Analysis Conclusion
Scattered incidences of abnormal feces (loose, mucoid, traces of fresh blood) Total observed: n = 15 Similar number of animals affected in each treated group compared to controls; abnormal feces already observed pre-treatment across all groups Not treatment related, no adverse event
Control group: n = 4
1X group: n = 5
3X group: n = 3
5X group: n = 3
Reduced body condition score (2 or 2–3 on a scale of 1–5) Total observed: n = 8 Similar (3X group, 5X group) or lower (1X group) number of animals affected compared to controls; no dose–response relationship Not treatment related, no adverse event
Control group: n = 3
1X group: n = 0
3X group: n = 3
5X group: n = 2
Localized hair thinning/pressure wound/wound Total observed: n = 6 Similar (1X group, 5X group) or lower (3X group) number of animals affected compared to controls; no dose–response relationship Not treatment related, no adverse event
Control group: n = 2
1X group: n = 3
3X group: n = 0
5X group: n = 1
Vomiting of food after first treatment, no other clinical findings Total observed: n = 1 Single case; no dose–response relationship; not observed following repeated treatment Not treatment related, no adverse event
Control group: n = 0
1X group: n = 1
3X group: n = 0
5X group: n = 0
Gastroenteritis with inappetence, dullness, vomit Total observed: n = 1 Single case; no dose–response relationship; not observed following repeated treatment Not treatment related, no adverse event
Control group: n = 0
1X group: n = 0
3X group: n = 1
5X group: n = 0